WO2014081709A3 - Methods of treating a disease or disorder associated with bruton's tyrosine kinase - Google Patents

Methods of treating a disease or disorder associated with bruton's tyrosine kinase Download PDF

Info

Publication number
WO2014081709A3
WO2014081709A3 PCT/US2013/070766 US2013070766W WO2014081709A3 WO 2014081709 A3 WO2014081709 A3 WO 2014081709A3 US 2013070766 W US2013070766 W US 2013070766W WO 2014081709 A3 WO2014081709 A3 WO 2014081709A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
disease
disorder associated
methods
bruton
Prior art date
Application number
PCT/US2013/070766
Other languages
French (fr)
Other versions
WO2014081709A2 (en
Inventor
Tom Daniel
Kenichi Takeshita
Kenneth Foon
Jay Mei
Original Assignee
Celgene Avilomics Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research, Inc. filed Critical Celgene Avilomics Research, Inc.
Priority to EP13856920.7A priority Critical patent/EP2922826A4/en
Publication of WO2014081709A2 publication Critical patent/WO2014081709A2/en
Publication of WO2014081709A3 publication Critical patent/WO2014081709A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK. In particular, the invention provides a method of treating, stabilizing or lessening the severity or progression of one or more diseases and conditions associated with BTK comprising administering to a patient in need thereof, Compound 1 (N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamin0)pyrimidin-4-ylamino)phenyl)acrylamide) or a pharmaceutically acceptable salt thereof, and lenalidomide.
PCT/US2013/070766 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase WO2014081709A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13856920.7A EP2922826A4 (en) 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261728701P 2012-11-20 2012-11-20
US201261728703P 2012-11-20 2012-11-20
US61/728,703 2012-11-20
US61/728,701 2012-11-20
US201361799761P 2013-03-15 2013-03-15
US61/799,761 2013-03-15
US201361870718P 2013-08-27 2013-08-27
US201361870720P 2013-08-27 2013-08-27
US61/870,718 2013-08-27
US61/870,720 2013-08-27

Publications (2)

Publication Number Publication Date
WO2014081709A2 WO2014081709A2 (en) 2014-05-30
WO2014081709A3 true WO2014081709A3 (en) 2015-07-16

Family

ID=50776661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/070766 WO2014081709A2 (en) 2012-11-20 2013-11-19 Methods of treating a disease or disorder associated with bruton's tyrosine kinase

Country Status (3)

Country Link
EP (1) EP2922826A4 (en)
TW (1) TW201427666A (en)
WO (1) WO2014081709A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201427668A (en) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc Methods of treating a disease or disorder associated with Bruton's tyrosine kinase
MX2015009952A (en) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Erk inhibitors and uses thereof.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN111057021B (en) * 2019-12-11 2023-05-23 中国药科大学 S-triazine compound, preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249092A1 (en) * 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US20120077832A1 (en) * 2010-08-10 2012-03-29 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
US20120087915A1 (en) * 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
WO2012078492A1 (en) * 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
US8206711B2 (en) * 1998-11-09 2012-06-26 Biogen Idec Inc. Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
WO2012100459A1 (en) * 2011-01-28 2012-08-02 广州盈升生物科技有限公司 Phosphorus substituted group-containing quinoline-like compound, its preparation process, medical composition containing the compound and application
WO2012135801A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206711B2 (en) * 1998-11-09 2012-06-26 Biogen Idec Inc. Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies
US20100249092A1 (en) * 2008-06-27 2010-09-30 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US20120087915A1 (en) * 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20120077832A1 (en) * 2010-08-10 2012-03-29 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
WO2012078492A1 (en) * 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012100459A1 (en) * 2011-01-28 2012-08-02 广州盈升生物科技有限公司 Phosphorus substituted group-containing quinoline-like compound, its preparation process, medical composition containing the compound and application
WO2012135801A1 (en) * 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2922826A4 *

Also Published As

Publication number Publication date
EP2922826A4 (en) 2016-08-03
TW201427666A (en) 2014-07-16
EP2922826A2 (en) 2015-09-30
WO2014081709A2 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
WO2014081712A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
WO2014081714A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
SA515360229B1 (en) Growth differentiation factor-8 inhibitors
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
CY1119420T1 (en) NEW THERAPEUTIC APPROACHES TO PARKINSON'S DISEASE TREATMENT
EA201590930A1 (en) DOSAGE FORMS OF RUXOLITINIB WITH Slow Release.
EA201490300A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamide in the BTK-Inhibitor
EA201391029A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF NEUROLOGICAL DISORDERS
EA201391017A1 (en) METHODS AND READY MEDICATION FORMS FOR THE TREATMENT OF ALZHEYMER
WO2014081709A3 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
MX2016000364A (en) Methods for treating or preventing ophthalmological conditions.
AR088570A1 (en) METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
MX355129B (en) Compounds and methods for treating aberrant adrenocartical cell disorders.
TN2017000158A1 (en) Carbazole derivatives
EA201490721A1 (en) Drug for the treatment of diseases of the anterior chamber of the eye, including rebamipid and tear-retaining agent
EA201401353A1 (en) BIOMARKERS TO DETERMINE AN EFFECTIVE RESPONSE RESPONSE TO THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)
EA201691020A1 (en) METHODS OF TREATMENT AND PREVENTION OF CALLED ALLOGEN ANTIBODIES OF CHRONIC DISEASE "TRANSPLANTAT AGAINST THE OWNER"
MY199237A (en) Methods of treating ocular conditions
MX2014005715A (en) N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl ]-benzamide for the treatment of chronic myelogenous leukemia.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
EA201990621A1 (en) CRYSTALLIC FORMS OF LYSYLOXIDASE-LIKE PROTEIN 2 INHIBITOR AND METHODS FOR PRODUCING
EA201790905A1 (en) METHOD FOR TREATING STATES CONNECTED WITH PGI2 RECEPTOR

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13856920

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013856920

Country of ref document: EP